<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_Linkoping_Sweden_Project skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><DIV id="top_title"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:Linkoping Sweden/Project</SPAN></H1></DIV><DIV id="HQ_page"><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><DIV class="topnav" id="myTopnav"><DIV class="mobile-menu"><CENTER><DIV class="topnav-bottom-content"><DIV id="mobile-only-text"><P>LiU iGEM 2017</P></DIV><DIV class="dropdown"><A href="https://2017.igem.org/Team:Linkoping_Sweden">Home</A></DIV><DIV class="dropdown"><SPAN>Team</SPAN><DIV class="dropdown-content"><A href="https://2017.igem.org/Team:Linkoping_Sweden/Team">Team</A><A href="https://2017.igem.org/Team:Linkoping_Sweden/Collaborations">Collaborations</A></DIV></DIV><DIV class="dropdown"><SPAN> Background </SPAN><DIV class="dropdown-content"><A href="https://2017.igem.org/Team:Linkoping_Sweden/Description"> Project Description</A><A href="https://2017.igem.org/Team:Linkoping_Sweden/Safety">Safety</A><A href="https://2017.igem.org/Team:Linkoping_Sweden/AlzheimersDisease"> Alzheimer's Disease </A></DIV></DIV><DIV class="dropdown"><SPAN> Project </SPAN><DIV class="dropdown-content"><A href="https://2017.igem.org/Team:Linkoping_Sweden/Design">Design</A><A href="https://2017.igem.org/Team:Linkoping_Sweden/Experiments">Experiments</A><A href="https://2017.igem.org/Team:Linkoping_Sweden/Notebook">Notebook</A><A href="https://2017.igem.org/Team:Linkoping_Sweden/Contribution">Contribution</A><A href="https://2017.igem.org/Team:Linkoping_Sweden/Model">Model</A><A href="https://2017.igem.org/Team:Linkoping_Sweden/Results">Results</A><A href="https://2017.igem.org/Team:Linkoping_Sweden/Attributions">Attributions</A></DIV></DIV><DIV class="dropdown"><SPAN>Parts</SPAN><DIV class="dropdown-content"><A href="https://2017.igem.org/Team:Linkoping_Sweden/Parts">Parts</A><A href="https://2017.igem.org/Team:Linkoping_Sweden/UnfinishedParts">Planned Parts</A></DIV></DIV><DIV class="dropdown"><SPAN>Human Practices</SPAN><DIV class="dropdown-content"><A href="https://2017.igem.org/Team:Linkoping_Sweden/Human_Practices">Overview</A><A href="https://2017.igem.org/Team:Linkoping_Sweden/HP/Silver">Silver HP</A><A href="https://2017.igem.org/Team:Linkoping_Sweden/HP/Gold_Integrated">Integrated and Gold</A><A href="https://2017.igem.org/Team:Linkoping_Sweden/Engagement">Public Engagement</A></DIV></DIV><DIV class="dropdown"><A href="https://2017.igem.org/Team:Linkoping_Sweden/Contact">Contact us</A></DIV><A href="javascript:void(0);" style="font-size:2em;" class="icon" onclick="menuButton()">☰</A></DIV></CENTER></DIV><DIV class="content-container"><DIV class="content"><H3> Summary </H3><P> 
                Around 100,000 people in Sweden and a total of 46,8 million in the world suffer from Alzheimer's disease [1,2]. The cause of the disease is still largely unknown [1]. The polypeptide amyloid-beta and the protein tau are two molecules that are known to be related to the development of the disease. These are found in the brain in and around our neurons and in Alzheimer's disease, they accumulate to form plaques and tangles respectively [3, 4]. 
Because these proteins are prone to aggregate they are hard to study in a laboratory environment. 
           </P><P> The aim of the project is to optimize the expression of the amyloid-beta and tau in Escherichia coli. Chaperones are proteins that can help other proteins to fold into their native three-dimensional shape, if Amyloid-beta and Tau are correctly folded they are less likely to aggregate. We will study four different chaperones to determine the optimal combination of chaperone system for expressing Amyloid-beta and Tau respectively. 
           </P><P> With our project, we hope to make a new model for expressing these proteins without aggregation. We also see a future for our model to be used to express other difficult proteins. 
</P><H4>Sources</H4><SMALL>1. Alzheimerfonden. Alzheimers sjukdom [Internet]. Cited 2017-06-15. Available from: http://www.alzheimerfonden.se/om_demens/alzheimers_sjukdom [in swedish] 
           </SMALL><SMALL>2. Alzheimer´s Disease International. Dementia statistics [Internet]. Cited 2017-06-27. Available from: https://www.alz.co.uk/research/statistics
           </SMALL><SMALL>3. Alzheimerfonden. Lexikon för Alzheimers sjukdom och andra demenssjukdomar [Internet]. Cited 2017-06-15. Available from: http://www.alzheimerfonden.se/om_demens/lexikon [in swedish] 
           </SMALL><SMALL>4. Bloom GS. Amyloid-β and TauThe Trigger and Bullet in Alzheimer Disease Pathogenesis. JAMA Neurol. 2014;71(4):505-508. doi:10.1001/jamaneurol.2013.5847 
           </SMALL></DIV></DIV><FOOTER class="footer"><DIV id="foot_text"><P style="text-align: center;">LiU iGEM is proudly sponsored by</P></DIV><DIV class="bottom-footer"><DIV class="foot-1">
    LiU iGEM
    
    Kårallen, Linköpings Universitet
    
    581 83 Linköping
    <A href="https://2017.igem.org/Team:Linkoping_Sweden/Contact" style="color: white;">Contact us</A></DIV><DIV class="foot-2"><A href="https://liu.se/en/about-liu" target="_blank" style="color: white;">About LiU</A><A href="https://liu.se/en/education" target="_blank" style="color: white;">Study in Linköping</A><A href="https://liu.se/en/research" target="_blank" style="color: white;">Research</A><A href="https://liu.se/en" target="_blank" style="color: white;">www.liu.se</A></DIV></DIV></FOOTER></DIV></DIV></DIV></DIV></DIV></DIV></BODY></HTML>